Donavon J. McConn

EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM

Weili Huang, Yvonne S. Lin, Donavon J. McConn et al. · Drug Metabolism and Disposition · 2004 · 175 citations

Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.

Donavon J. McConn, Yvonne S. Lin, Kyle E. Allen et al. · PubMed · 2004 · 85 citations

Cytochromes P450 3A4, Pharmacotherapy, Physiologically-based Pharmacokinetic Modeling +17

DIFFERENCES IN THE INHIBITION OF CYTOCHROMES P450 3A4 AND 3A5 BY METABOLITE-INHIBITOR COMPLEX-FORMING DRUGS

Donavon J. McConn, Yvonne S. Lin, Kyle E. Allen et al. · Drug Metabolism and Disposition · 2004 · 85 citations

An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction

Melinda J. Reese, Robert M. Wurm, Keith T. Muir et al. · Drug Metabolism and Disposition · 2008 · 82 citations

Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia

H Reichard, Hans H. Schiffer, Holger Monenschein et al. · Journal of Medicinal Chemistry · 2021 · 35 citations · Full text